REGENXBIO Inc.

Welcome, everyone, to the Q3 2024 Regenexx BIO Earnings Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. At this time, I'd like to turn the conference over to Patrick Christmas, Chief Legal Officer of Regenexx BIO. Please go ahead.

Good afternoon, and thank you for joining us today.

Earlier this afternoon, Regenexx BIO released financial and operating results for the third quarter, and it's September 30, 2024. The press release is available on our website at www.regenexxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, leave, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involves certain risks and uncertainties. These risks are described in the risk factors. In the management's discussion and analysis section, Regenexx BIOS annual report on Form 10-K for the full year ended December 31, 2023, and comparable risk factor sections of Regenexx BIOS quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the FCC's website. Any information we provide on this conference call is provided only as of the date of this call and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events, or otherwise. Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not afford to project financial positions or operating results of the company. Actual results may differ materially. I will now turn the call over to Curran Simpson, President and CEO of Regenexx.